According to a post on the FDA’s website, Bristol Myers’ repotrectinib received orphan designation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers Squibb (NYSE:BMY) Shrugs off Analyst Cut
- Bristol Myers downgraded to Hold from Buy at Societe Generale
- Bristol Myers reports FDA approves Opdivo for first-line metastatic UC treatment
- Healthcare Stocks Retreat after New Task Force Is Formed
- 2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4